My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 305

    1.

    Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

    Ann Intern Med. 1999 Aug 3;131(3):174-81.PMID: 10428733 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group.

    Ann Intern Med. 2005 Jan 18;142(2):105-14.PMID: 15657158 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

    Int J Cancer. 2000 Sep 1;87(5):741-9.PMID: 10925370 [PubMed - indexed for MEDLINE]Related articles

    4.

    Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.

    Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.

    Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.PMID: 12397752 [PubMed - indexed for MEDLINE]Related articles

    5.

    Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

    Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

    Ann Intern Med. 1998 Jul 15;129(2):94-9.PMID: 9669992 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.

    Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, Kojima J, Tanaka S.

    J Epidemiol. 2000 Jul;10(4):234-40.PMID: 10959605 [PubMed - indexed for MEDLINE]Related articles

    7.

    Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.

    Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.

    Liver Int. 2005 Feb;25(1):85-90.PMID: 15698403 [PubMed - indexed for MEDLINE]Related articles

    8.

    Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M.

    Ann Intern Med. 2000 Apr 4;132(7):517-24.PMID: 10744587 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

    Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

    J Viral Hepat. 2004 Mar;11(2):148-56.PMID: 14996350 [PubMed - indexed for MEDLINE]Related articles

    10.

    Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

    Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

    Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.PMID: 16234069 [PubMed - indexed for MEDLINE]Related articles

    11.

    Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.

    Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW.

    Scand J Gastroenterol. 2006 Sep;41(9):1087-94.PMID: 16938723 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy]

    Fujiyama S, Tanaka M.

    Rinsho Byori. 2000 Jan;48(1):5-13. Japanese. PMID: 10756668 [PubMed - indexed for MEDLINE]Related articles

    13.

    Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.

    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K.

    J Hepatol. 1999 Apr;30(4):653-9.PMID: 10207807 [PubMed - indexed for MEDLINE]Related articles

    14.

    Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

    Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y, Omata M.

    Gut. 2004 Mar;53(3):425-30.PMID: 14960528 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

    Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.

    Ann Intern Med. 2007 May 1;146(9):649-56.PMID: 17470833 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Interferon therapy prolonged life expectancy among chronic hepatitis C patients.

    Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M.

    Gastroenterology. 2002 Aug;123(2):483-91.PMID: 12145802 [PubMed - indexed for MEDLINE]Related articles

    17.

    Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.

    Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H.

    J Gastroenterol Hepatol. 2001 Apr;16(4):406-15.PMID: 11354279 [PubMed - indexed for MEDLINE]Related articles

    18.

    Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.

    Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, Kobashi H, Kobatake T, Tanaka R, Tomita M, Senoh T, Kawaguchi M, Shimoe T, Manabe K, Kita K, Shimamura J, Sakaguchi K, Shiratori Y.

    Liver Int. 2004 Dec;24(6):603-10.PMID: 15566511 [PubMed - indexed for MEDLINE]Related articles

    19.

    Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.

    Shindo M, Ken A, Okuno T.

    Cancer. 1999 May 1;85(9):1943-50.PMID: 10223234 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

    Omata M, Yoshida H, Shiratori Y.

    Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.PMID: 16234063 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity